Promoters are individuals or entities who establish and oversee the initiation and growth of a business venture. They often provide the initial capital, develop the business idea, and make strategic decisions to ensure its success. Promoters typically have a vested interest in the company’s performance and may hold significant ownership stakes.
Here are stocks in which the promoter decreased their stake up to 6.19% in Q1FY26:
1. K P R Mill Ltd
K.P.R. Mill Limited is a vertically integrated apparel manufacturing company. The Company is engaged in the manufacture and sale of Yarn, knitted fabric, readymade garments, and wind power. Its segments include Textile, Sugar, and Others.
With a market capitalization of Rs 41,501 crore, the shares were trading at Rs 1,214 per share, increasing around 0.83 percent as compared to the previous closing price. The promoter of the company decreased its stake by 3.16 percent, from 70.68 percent in Q4FY25 to 67.52 percent in June 2025. Additionally, 6.93 percent is owned by retail investors, 18.98 percent is held by domestic institutional investors, and 6.55 percent is owned by foreign institutional investors.
2. Hindustan Zinc Ltd
Hindustan Zinc Limited is engaged in exploring, extracting, processing minerals, and manufacturing metals and alloys. The Company produces zinc, lead, silver, commercial power, and alloys. Its segments include Zinc, Lead, Silver & others, and Wind energy.
With a market capitalization of Rs 1.84 lakh crore, the shares were trading at Rs 437 per share, increasing around 0.45 percent as compared to the previous closing price. The promoter of the company decreased its stake by 1.58 percent, from 63.42 percent in Q4FY25 to 61.84 percent in June 2025. Additionally, 4.07 percent is owned by retail investors, 4.81 percent is held by domestic institutional investors, 1.36 percent is owned by foreign institutional investors, and lastly, 27.92 percent is owned by the Government.
Also read: EMS stock in which Govt of Singapore bought fresh stake to keep an eye on
3. Biocon Ltd
Biocon Limited focuses on treating diabetes, cancer, and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics, and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule active pharmaceutical ingredients (APIs) in India and several key global markets.
With a market capitalization of Rs 53,017 crore, the shares were trading at Rs 397 per share, increasing around 0.51 percent as compared to the previous closing price. The promoter of the company decreased its stake by 6.19 percent, from 60.64 percent in Q4FY25 to 54.45 percent in June 2025. Additionally, 16.91 percent is owned by retail investors, 21.45 percent is held by domestic institutional investors, and 7.01 percent is owned by foreign institutional investors.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
